Media stories about GTX (NASDAQ:GTXI) have been trending somewhat positive on Wednesday, according to Accern Sentiment. The research firm identifies negative and positive news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. GTX earned a media sentiment score of 0.20 on Accern’s scale. Accern also gave media stories about the biopharmaceutical company an impact score of 45.8156371391056 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Shares of GTXI stock traded down $0.38 on Wednesday, hitting $19.39. The company’s stock had a trading volume of 162,931 shares, compared to its average volume of 102,746. The firm has a market capitalization of $430.11, a PE ratio of -11.08 and a beta of 1.65. GTX has a 12 month low of $2.73 and a 12 month high of $23.40.
GTX (NASDAQ:GTXI) last announced its quarterly earnings data on Monday, March 12th. The biopharmaceutical company reported ($0.43) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.48) by $0.05. equities research analysts expect that GTX will post -1.78 EPS for the current fiscal year.
In other news, VP Henry Patton Doggrell sold 4,965 shares of the stock in a transaction on Friday, January 5th. The stock was sold at an average price of $11.33, for a total transaction of $56,253.45. Following the completion of the sale, the vice president now owns 54,804 shares in the company, valued at approximately $620,929.32. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Marc Steven Hanover sold 7,309 shares of the stock in a transaction on Friday, January 5th. The shares were sold at an average price of $11.33, for a total value of $82,810.97. Following the completion of the sale, the chief executive officer now owns 129,990 shares of the company’s stock, valued at approximately $1,472,786.70. The disclosure for this sale can be found here. Insiders sold a total of 15,364 shares of company stock valued at $174,074 over the last three months. Corporate insiders own 41.20% of the company’s stock.
GTX Company Profile
GTx, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecules for the treatment of breast and prostate cancer, and other medical conditions. It focuses on the development of selective androgen receptor modulators (SARMs) for the treatment of breast cancer, stress urinary incontinence (SUI), and Duchenne muscular dystrophy (DMD); and selective androgen receptor degraders (SARDs) to treat progressive castration-resistant prostate cancer (CRPC).
Receive News & Ratings for GTX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GTX and related companies with MarketBeat.com's FREE daily email newsletter.